Management, control, and decision making in unexpected recurrent venous thromboembolism in COVID-19: a case report.

Published in: Journal of medical case reports (2023)

In the case of unexpected recurrent venous thromboembolism in coronavirus disease 2019, especially when patients are taking rivaroxaban or other new oral anticoagulants, such drugs should be substituted by warfarin, with routine follow-up, to maintain the value of prothrombin time and international normalized ratio within the therapeutic range.

Keyphrases

venous thromboembolism
coronavirus disease
direct oral anticoagulants
atrial fibrillation
oral anticoagulants
end stage renal disease
ejection fraction
sars cov
newly diagnosed
respiratory syndrome coronavirus
prognostic factors
peritoneal dialysis
pulmonary embolism